Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1943 1
1944 2
1946 3
1948 3
1949 3
1950 1
1951 1
1952 1
1955 2
1956 1
1957 5
1958 6
1959 8
1960 2
1961 6
1962 18
1963 12
1964 12
1965 14
1966 12
1967 14
1968 10
1969 15
1970 15
1971 17
1972 28
1973 23
1974 21
1975 33
1976 27
1977 36
1978 30
1979 31
1980 36
1981 45
1982 45
1983 51
1984 46
1985 49
1986 77
1987 109
1988 86
1989 89
1990 89
1991 107
1992 127
1993 147
1994 150
1995 160
1996 224
1997 181
1998 254
1999 238
2000 272
2001 347
2002 421
2003 445
2004 572
2005 707
2006 839
2007 915
2008 998
2009 1065
2010 1368
2011 1556
2012 1717
2013 1823
2014 1942
2015 2165
2016 2173
2017 2371
2018 2491
2019 2859
2020 3398
2021 4025
2022 4315
2023 1969

Text availability

Article attribute

Article type

Publication date

Search Results

38,641 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer.
Cortés J, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Huang CS, Kim JH, Chiu JWY, Pedrini JL, Lee C, Liu Y, Cathcart J, Bako E, Verma S, Hurvitz SA; DESTINY-Breast03 Trial Investigators. Cortés J, et al. Among authors: huang cs. N Engl J Med. 2022 Mar 24;386(12):1143-1154. doi: 10.1056/NEJMoa2115022. N Engl J Med. 2022. PMID: 35320644 Clinical Trial.
Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.
von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, Wolmark N, Rastogi P, Schneeweiss A, Redondo A, Fischer HH, Jacot W, Conlin AK, Arce-Salinas C, Wapnir IL, Jackisch C, DiGiovanna MP, Fasching PA, Crown JP, Wülfing P, Shao Z, Rota Caremoli E, Wu H, Lam LH, Tesarowski D, Smitt M, Douthwaite H, Singel SM, Geyer CE Jr; KATHERINE Investigators. von Minckwitz G, et al. Among authors: huang cs. N Engl J Med. 2019 Feb 14;380(7):617-628. doi: 10.1056/NEJMoa1814017. Epub 2018 Dec 5. N Engl J Med. 2019. PMID: 30516102 Clinical Trial.
Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial.
Huang C, Liu H, Hu Y, Sun Y, Su X, Cao H, Hu J, Wang K, Suo J, Tao K, He X, Wei H, Ying M, Hu W, Du X, Yu J, Zheng C, Liu F, Li Z, Zhao G, Zhang J, Chen P, Li G; Chinese Laparoscopic Gastrointestinal Surgery Study (CLASS) Group. Huang C, et al. JAMA Surg. 2022 Jan 1;157(1):9-17. doi: 10.1001/jamasurg.2021.5104. JAMA Surg. 2022. PMID: 34668963 Free PMC article. Clinical Trial.
Low-Density Lipoprotein Cholesterol and Mortality in Patients With Intracerebral Hemorrhage in Taiwan.
Wen CP, Lee YC, Sun YT, Huang CY, Tsai CH, Chen PL, Chang WL, Yeh PY, Wei CY, Tsai MJ, Sun Y, Lin CH, Lee JT, Lai TC, Lien LM, Lin MC, Lin CL, Lee JH, Wang HK, Hsu CY; Taiwan Stroke Registry Investigators. Wen CP, et al. Among authors: huang cy. Front Neurol. 2022 Jan 17;12:793471. doi: 10.3389/fneur.2021.793471. eCollection 2021. Front Neurol. 2022. PMID: 35113980 Free PMC article.
Uremic frost.
Huang CW, Wei KC. Huang CW, et al. J Formos Med Assoc. 2023 Apr 24:S0929-6646(23)00114-6. doi: 10.1016/j.jfma.2023.04.006. Online ahead of print. J Formos Med Assoc. 2023. PMID: 37100700 Free article. No abstract available.
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Zhong WZ, Wang Q, Mao WM, Xu ST, Wu L, Shen Y, Liu YY, Chen C, Cheng Y, Xu L, Wang J, Fei K, Li XF, Li J, Huang C, Liu ZD, Xu S, Chen KN, Xu SD, Liu LX, Yu P, Wang BH, Ma HT, Yan HH, Yang XN, Zhou Q, Wu YL; ADJUVANT investigators. Zhong WZ, et al. Among authors: huang c. Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21. Lancet Oncol. 2018. PMID: 29174310 Clinical Trial.
Reply by Authors.
Ka-Fung Chiu P, Leow JJ, Chiang CH, Mo A, Zhang K, Hsieh PF, Zhu Y, Lam W, Tsang WC, Fan YH, Lin TP, Chan TY, Leung CH, Yen-Chun Teoh J, Sau-Kwan Chu P, Zhu G, Ye DW, Wu HC, Tan TW, Hok-Leung Tsu J, Ng CF, Chiong E, Huang CY. Ka-Fung Chiu P, et al. Among authors: huang cy. J Urol. 2023 May 4:101097JU000000000000345002. doi: 10.1097/JU.0000000000003450.02. Online ahead of print. J Urol. 2023. PMID: 37139611 No abstract available.
Uremic leontiasis ossea.
Liang TJ, Huang CW. Liang TJ, et al. Among authors: huang cw. Postgrad Med J. 2022 Dec 1;98(1166):e37. doi: 10.1136/postgradmedj-2021-140837. Postgrad Med J. 2022. PMID: 37063003 No abstract available.
Recent advances in vascularized tumor-on-a-chip.
Huang CBX, Tu TY. Huang CBX, et al. Front Oncol. 2023 Mar 30;13:1150332. doi: 10.3389/fonc.2023.1150332. eCollection 2023. Front Oncol. 2023. PMID: 37064144 Free PMC article. Review.
The androgen receptor in bladder cancer.
Chen J, Huang CP, Quan C, Zu X, Ou Z, Tsai YC, Messing E, Yeh S, Chang C. Chen J, et al. Among authors: huang cp. Nat Rev Urol. 2023 Apr 18. doi: 10.1038/s41585-023-00761-y. Online ahead of print. Nat Rev Urol. 2023. PMID: 37072491 Review.
38,641 results
You have reached the last available page of results. Please see the User Guide for more information.